An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan

Documenti analoghi

• The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
  di: Cheng, Wen-Chien, et al.
  Pubblicazione: (2021)
• Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
  di: Wu, Shang-Gin, et al.
  Pubblicazione: (2018)
• The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
  di: Tseng, Jeng-Sen, et al.
  Pubblicazione: (2016)
• T790M and acquired resistance of EGFR TKI: a literature review of clinical reports
  di: Ma, Chunyan, et al.
  Pubblicazione: (2011)
• The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma
  di: Zhang, Qiuyi, et al.
  Pubblicazione: (2016)